The impact of comorbidity on long-term results of above-knee prosthetic femoropopliteal bypass for intermittent claudication

International Angiology

Volumn 24, Issue 3, 2005, Pages 245-249

  Pedersen, Gustav ^a,b   Laxdal, E ^a,b   Hagala, M ^a   Aune, S ^a  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Femoral artery; Intermittent claudication; Popliteal artery

Indexed keywords

CREATININE;

ABOVE KNEE PROSTHESIS; ADULT; AGED; ARTICLE; BRAIN INFARCTION; CIGARETTE SMOKING; COMORBIDITY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; FEMOROPOPLITEAL BYPASS; GRAFT PATENCY; HUMAN; INTERMITTENT CLAUDICATION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; PATIENT SELECTION; PREOPERATIVE EVALUATION; PROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; BLOOD VESSEL PROSTHESIS IMPLANTATION; COMORBIDITY; CREATININE; DIABETIC ANGIOPATHIES; FEMALE; FEMORAL ARTERY; GRAFT OCCLUSION, VASCULAR; HUMANS; HYPERTENSION; INTERMITTENT CLAUDICATION; MALE; MIDDLE AGED; POPLITEAL ARTERY; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME;

EID: 27744449933     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Jensen LP. Intermittent claudication. Conservative treatment, endovascular repair or open surgery for femoropopliteal disease. Ann Chir Gynaecol 1998;87:137-40.
2. Burger DH, Kappetein AP, Van Bockel JH, Breslau PJ. A prospective randomized trial comparing vein with polytetrafluoroethylene in above-knee femoropopliteal bypass grafting. J Vasc Surg 2000;32:278-83.
3. Klinkert P, Post PN, Breslau PJ, Van Bockel JH. Saphenous vein versus PTFE for above-knee femoropopliteal bypass. A review of the literature. Eur J Vasc Endovasc Surg 2004;27:357-62.
4. Aquino R, Johnnides C, Makaroun M, Whittle JC, Muluk VS, Kelley ME et al. Natural history of claudication: long-term serial follow-up study of 1244 claudicants. J Vasc Surg 2001;34:962-70.
5. Statistics Norway. Mortality rates, by sex and age. http://www.ssb.no/english/yearbook/tab/t-020210-075.html. 2002.
6. Rosenthal D, Evans RD, McKinsey J, Seagraves MA, Lamis PA, Clark MD et al. Prosthetic above-knee femoropopliteal bypass for intermittent claudication. J Cardiovasc Surg (Torino) 1990;31:462-8.
7. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to life and limb. Semin Vasc Surg 1999;12: 123-37.
8. Miyazaki K, Nishibe T, Sata F, Miyazaki YI, Kudo FA, Flores J et al. Prosthetic grafts for above-knee femoropopliteal bypass. A multicenter retrospective study of 564 grafts. Int Angiol 2002;21:145-51.
9. Korn P, Hoenig SJ, Skillman JJ, Kent KC. Is lower extremity revascularization worthwhile in patients with end-stage renal disease? Surgery 2000;128:472-9.
10. Baele HR, Piotrowski JJ, Yuhas J, Anderson C, Alexander JJ. Infrainguinal bypass in patients with end-stage renal disease. Surgery 1995;117:319-24.
11. Abbott WM, Green RM, Matsumoto T, Wheeler JR, Miller N, Veith FJ et al. Prosthetic above-knee femoropopliteal bypass grafting: results of a multicenter randomized prospective trial. Above-Knee Femoropopliteal Study Group. J Vasc Surg 1997;25:19-28.
12. Evans LE, Webster MW, Brooks DH, Bahnson HT. Expanded polytetrafluoroethylene femoropopliteal grafts: forty-eight- month follow-up. Surgery 1981;89:16-22.
13. Prendiville EJ, Yeager A, O'Donnell TF Jr, Coleman JC, Jaworek A, Callow AD et al. Long-term results with the above-knee popliteal expanded polytetrafluoroethylene graft. J Vasc Surg 1990;11:517-24.
14. Ameli FM, Stein M, Provan JL, Prosser R. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 1989;1989:20-5.
15. Wiseman S, Kenchington G, Dain R, Marshall CE, McCollum CN, Greenhalgh RM et al. Influence of smoking and plasma factors on patency of femoropopliteal vein grafts. BMJ 1989;299:643-6.